Home / Resources (page 32)

Resources

RESOURCES

Aiming for MASH Resolution: How to Use GLP‑1s in Liver‑First Diabetes Care

A doctor holding a liver model with GLP-1 injection tools, healthy food, and a glucometer, symbolizing GLP‑1 MASH treatment in diabetes care.

What if the key to resolving both diabetes and liver disease lies in a single therapeutic approach? As rates of metabolic dysfunction-associated steatohepatitis (MASH) rise among people with type 2 diabetes, many clinicians are rethinking how they prioritize treatment. Rather than treating glucose and liver health in silos, combining therapies …

Read More »

AI for Insulin Management: Letting Algorithms Help—Without Handing Over the Wheel

AI-driven diabetes tools including CGM sensor, smartphone displaying glucose data, and insulin pump with a digital brain hologram representing AI analysis.

Artificial intelligence (AI) is transforming many aspects of diabetes care, and smart insulin management powered by AI is quickly becoming one of its most promising innovations. Tools that read continuous glucose monitor (CGM) data and suggest insulin changes are rapidly entering clinical use. But while these tools are powerful, they …

Read More »

GLP‑1s in Menopause: Using Incretins to Protect Cardiometabolic Health in Midlife

Middle-aged woman smiling in a medical office, holding a medication bottle to represent GLP‑1 therapy during menopause.

Menopause marks a major transition in a woman’s life, defined not only by the end of menstrual cycles but also by profound hormonal and metabolic changes. One often under‑recognized shift is the acceleration of cardiometabolic risk. Women in midlife frequently experience increased central adiposity, changes in glucose regulation, rising blood …

Read More »

GLP‑1s and Bone Health: Do Incretins Protect or Put Patients at Risk?

Illustration showing a glowing skeleton, GLP‑1 medications, porous bone models, and a balance scale highlighting bone health risks.

Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have transformed type 2 diabetes management by improving blood sugar control and promoting weight loss. Yet as clinical use grows, so does interest in how GLP‑1 medications affect skeletal health — particularly their impact on bone density, remodeling, and fracture risk. This article unpacks …

Read More »

GLP‑1s and Asthma: Can Metabolic Drugs Help Calm the Airways?

GLP-1 injection pen, asthma inhaler, and inflamed lungs with molecular structures in a scientific setting

Asthma is a chronic inflammatory disease of the airways that affects millions worldwide and often overlaps with metabolic conditions such as obesity and type 2 diabetes. Recently, interest has grown in whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs)—a class of drugs commonly used to manage diabetes and obesity—could help reduce …

Read More »

GLP‑1s and Liver Disease: Rethinking MASLD Care Beyond Obesity and A1C

3D liver with fatty deposits, GLP-1 injection pen, stethoscope, molecular structures, and test results for liver enzymes

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

Read More »

Inside the ADA 2026 Guidelines: A New Cardiometabolic Roadmap for Diabetes Care

Medical tools including a glucose meter, stethoscope, and ADA 2026 Guidelines clipboard, with digital icons representing cardiometabolic health

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …

Read More »

Prescribing GLP‑1s for Obesity Without Diabetes: How to Treat “Normoglycemic” Risk

A doctor holding a GLP‑1 injection pen while consulting with a woman about obesity treatment, surrounded by medical tools and healthy food.

In recent years, GLP‑1-based treatments for obesity have evolved from being primarily a diabetes-focused strategy to becoming a powerful tool for managing weight and reducing cardiometabolic risk—especially in individuals without type 2 diabetes. This growing trend is shifting how clinicians identify and manage obesity, moving beyond A1C levels to a …

Read More »

GLP‑1s and Depression: Could an Incretin Help Lift Mood?

Illustration of a human head split in half, showing stormy depression on one side and bright, healthy brain activity on the other, with GLP-1 medication and insulin pen in the foreground.

The potential link between GLP‑1 therapies and depression has sparked growing interest among clinicians and researchers. If you’ve ever wondered whether glucagon‑like peptide‑1 (GLP‑1) receptor agonists could positively influence mood, you’re not alone. Early research suggests these medications may ease depressive symptoms by dampening inflammation and influencing brain signaling, though …

Read More »